奥浦迈: 奥浦迈：董事会关于评估机构的独立性、评估假设前提的合理性、评估方法与评估目的的相关性以及评估定价的公允性的说明

Core Viewpoint - The company plans to acquire 100% equity of Pengli Bio-pharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds from no more than 35 specific investors [1][2]. Group 1: Transaction Overview - The acquisition involves multiple investment entities, including PharmaLegacy Hong Kong Limited and several limited partnerships [1]. - The transaction is referred to as "this transaction," which includes both the share issuance and cash payment for asset acquisition [2]. Group 2: Assessment and Evaluation - The company has appointed Shanghai Dongzhou Asset Appraisal Co., Ltd. as the asset evaluation agency for this transaction, ensuring the agency's independence and compliance with relevant regulations [2][3]. - The evaluation methods used include the income approach and market approach, with the income approach being selected for the final valuation [3]. - The assessment aims to determine the market value of the target assets as of the evaluation benchmark date, providing a basis for pricing in the transaction [3]. Group 3: Conclusion of the Board - The board concludes that the evaluation agency is independent, the assumptions for the evaluation are reasonable, and the methods used are relevant to the evaluation purpose, resulting in a fair pricing conclusion [4].